PRESSENSA®

Quality Dermal Solutions

PUBLIC TECHNICAL DATASHEET

SKU: PRS-3198 | v1.0.0 | EN

Etternity Dermal S.L. | Madrid, Spain

Intense C VitaSerum

Line: Retail Skincare · Home Care | Presentation: Dermocosmetic daily home care format



Formulated to stimulate the production of collagen and elastin. Among its components figures the ARGIRELOX(TM) (latest generation peptide) which acts synergistically to combat wrinkles, signs of ageing and the appearance of expression lines, whereby the skin...

KEY ACTIVE INGREDIENTS

- Formulated to stimulate the production of collagen and elastin. Among its components figures the ARGIRELOX(TM) (latest generation peptide) which acts synergistically to combat wrinkles, signs of ageing and the appearance of expression lines, whereby the skin becomes softer, more flexible. Vitamin C: magnesium ascorbyl phosphate, a powerful antioxidant that protects against the harmful effects of free radicals, helps protect and repair the skin, stimulate cell renewal and promote healthy circulation.
- ARGIRELOX(TM) PEPTIDE - It addresses two fundamental factors to relax muscle contraction and reduce wrinkles. Firstly, by reducing the acetylcholine release, and secondly, by blocking the entry of calcium ions.
- VITAMIN C - High antioxidant activity, acts by capturing and deactivating oxidants and free radicals in the skin, increasing skin elasticity and promoting collagen synthesis. Pigment: suppression of skin pigmentation process and degradation of melanin.
- HYALURONIC ACID - Full moisturizing and increase the dermal volume

COSMETIC / CLINICAL INDICATIONS

- Intense C VitaSerum
- Serum anti-ageing
- ROSEHIP EXTRACT - Multivitamins to delays signs of premature ageing and wrinkles.
- ORGANIC SILICA - Tightening and younger look skin.

REGULATORY & QUALITY GOVERNANCE

Status: APPROVED (2026-11-26) | Reviewer: Etternity Dermal, S.L. · Technical Direction
Regulatory Classification: Cosmetic - Reg. (EC) 1223/2009 | Audience: Daily Home Care
Claims / Regulatory Standard: Regulation (EC) No 1223/2009 · Regulation (EU) No 655/2013 | Markets: EU, MENA, LATAM, CIS
RESTRICTED DOCUMENTATION NOTICE: Full clinical injection/needling protocols, SDS and regulatory dossiers are excluded from public builds and provided strictly via controlled access.